ID: ALA144196

Max Phase: Preclinical

Molecular Formula: C26H32N6O3

Molecular Weight: 476.58

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(Cn2c(/N=C3/CCCN3C)nc3c2c(=O)n(CC2CC2)c(=O)n3CC2CC2)cc1

Standard InChI:  InChI=1S/C26H32N6O3/c1-29-13-3-4-21(29)27-25-28-23-22(30(25)14-19-9-11-20(35-2)12-10-19)24(33)32(16-18-7-8-18)26(34)31(23)15-17-5-6-17/h9-12,17-18H,3-8,13-16H2,1-2H3/b27-21-

Standard InChI Key:  NQNCGLJSKXRTET-MEFGMAGPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 476.58

Molecular Weight (Monoisotopic): 476.2536

AlogP: 2.99

#Rotatable Bonds: 8

Polar Surface Area: 86.65

Molecular Species: NEUTRAL

HBA: 8

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.96

CX LogP: 3.15

CX LogD: 3.13

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.50

Np Likeness Score: -0.94

References

1. Buckle DR, Arch JR, Connolly BJ, Fenwick AE, Foster KA, Murray KJ, Readshaw SA, Smallridge M, Smith DG..  (1994)  Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine.,  37  (4): [PMID:8120866] [10.1021/jm00030a007]

Source

Source(1):

• Scientific Literature